SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs falls after USFDA inspects Andhra Pradesh facility of its arm

13 Dec 2023 Evaluate

Laurus Labs is currently trading at Rs. 379.20, down by 8.85 points or 2.28% from its previous closing of Rs. 388.05 on the BSE.

The scrip opened at Rs. 376.75 and has touched a high and low of Rs. 383.95 and Rs. 373.15 respectively. So far 75238 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 417.85 on 09-Aug-2023 and a 52 week low of Rs. 279.65 on 28-Apr-2023.

Last one week high and low of the scrip stood at Rs. 396.75 and Rs. 373.15 respectively. The current market cap of the company is Rs. 20378.30 crore.

The promoters holding in the company stood at 27.20%, while Institutions and Non-Institutions held 35.04% and 37.76% respectively.

Laurus Labs’ wholly owned subsidiary -- Laurus Synthesis (LSPL) has underwent the United States Food and Drug Administration (USFDA) inspection for the manufacturing facility in Parawada, Anakapalli, near Visakhapatnam, Andhra Pradesh. The inspection was conducted from December 4, 2023 to December 12, 2023. It has been issued a Form 483 with five observations and the Company will address the observations within stipulated timelines.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.


Laurus Labs Share Price

1388.60 -1.90 (-0.14%)
12-Jun-2026 10:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.45
Dr. Reddys Lab 1274.15
Cipla 1387.70
Zydus Lifesciences 1112.80
Lupin 2273.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: